Opinion
Lipman: Synbio cell engineering as software is mostly marketing
“Many of the sort of publics in bio companies or the leadings in bio companies will talk about their, you know, cell engineering platform as if it's a software platform. We're really not there yet. It's more marketing than anything else in my opinion at the mom…”
Prediction Held up
Lipman: Most lab-grown meat startups will fail to reach commercial scale
“I'm anticipating that the vast majority will not be able to reach commercial scale and not be able to reach the market, so we'll either see a bunch of consolidation or a bunch of dead companies in the wake of whatever reckoning may be coming.”
Opinion
Lipman: Carbon-neutral products no longer strictly require price parity
“No, I think that's something that's changed in the environment is that
you don't necessarily have to be at price parity. It seems like in some of these industries or some of these products to be successful. So
It seems like consumers and, you know, certain …”
Assertion Partly supported
Lipman: Downstream processing accounts for most industrial biomanufacturing costs
“Most of the cost actually comes in the downstream processing. So after you grow up these cells in these big steel tanks the vast majority of costs come after that phase where you have to process this wet biomass and spin it down and treat it and purify it.”
Prediction Not checkable as stated
Lipman: Animal agriculture is never going to completely disappear
“And I don't think animal agriculture is ever going to go away.”
Prediction Not checkable as stated
Lipman: Cultured meat will not achieve an affordable price point at scale
“Technically they may be able to, but I don't think that it will come out at any affordable price at the end of that scaling process.”
Prediction Not checkable as stated
Lipman: Lab-grown meat will struggle to gain non-coastal consumer adoption
“And I think lab grown meat is all, is going to really struggle to you know, get consumers on board, especially not coastal consumers, not the ones on the blue coasts.”
Insight
Ari Lipman: Low-value commodities present severe market entry hurdles for biotech
“If you're making something that's super low value it's pretty hard to break into a new market.”
Assertion Not checkable as stated
Lipman: Microbial nitrogen fertilizer additives already see strong field use
“I think these, that my, that specific microbial additive is really exciting, and that, as far as I can tell, it's already getting a lot of use out in the field”
Insight
Lipman: Synbio startups should prioritize niche, high-value markets
“You know, you always want to try to own a larger portion of a small market than try to own a small portion of a large market, at least at the outset. So I think, and that has been the tradition across the biotech industry and across synthetic biology is go for…”
Opinion
Lipman: Bioplastics economics cannot yet displace cheap petroleum polymers
“Biological systems are actually pretty good at making polymers, certain kinds of polymers. But the problem is we've gotten so used to just extremely cheap polymers and plastics over the last, you know, 50 years that you know, entering into these commodity mark…”
Assertion Supported
Lipman: Bioremediation relies mostly on wild, not engineered, microbes
“We already use microbes to help with things like oil spills, so there's already a field called bioremediation today which is, you know, fairly robust, but for the most part, these microbes we're using today to kind of break down contaminants are wild microbes …”
Assertion Supported
Lipman: Biotech investment remains predominantly concentrated in pharma
“The majority of kind of applications and investment in biotech broadly is still related to pharma.”
